

FY2016 2Q Consolidated Financial Overview (IFRS based)

CHUGAI PHARMACEUTICAL CO., LTD.
Executive Vice President, CFO
Yoshio Itaya

July 21/22, 2016



Forward-Looking Statements

This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company’s businesses.

Note: Amounts shown in this report are rounded to the nearest 0.1 billion yen
Variance and % are calculated based on the amounts shown



2Q Results Summary

■ Revenues: 247.5 billion yen (+7.3, +3.0% YoY)

- Domestic sales excl. Tamiflu: increase due to steady growth of new products and mainstay products (+5.1, +2.8%)
- Overseas sales: decrease due to impact of supply price reduction on Actemra export, etc. (-1.0, -2.1%)
- Royalties and other operating income: increase due to Actemra-related revenues, etc. (+2.8, +37.3%)

■ Cost of sales / Operating expenses (Core basis)

- Cost of sales: the ratio to sales worsened due to HIP revision and impact of supply price reduction on Actemra export, etc. (+2.3% points, from 50.1% to 52.4%)
- Operating expenses: increase mainly due to increase of research and development expenses related to the progress of projects (+1.3, +1.7%)

■ Profits

- IFRS results: operating profit 43.5 billion yen (+0.3, +0.7%)
net income 32.0 billion yen (+1.2, +3.9%)
- Core results: operating profit 44.1 billion yen (-1.8, -3.9%)
net income 32.4 billion yen (-0.1, -0.3%)
- Core EPS (JPY): 58.45 (+0.15, +0.3%)



IFRS and Core Results Jan-Jun

(Billion JPY)	IFRS results	Non-core items		Core results
	2016 Jan. - Jun.	Intangible assets	Others	2016 Jan. - Jun.
Revenues	247.5			247.5
Sales	237.2			237.2
Royalties and other operating income	10.3			10.3
Cost of sales	-125.0	+0.6		-124.4
Gross profit	122.5	+0.6		123.1
Operating expenses	-79.0	+0.0		-79.0
Marketing and distribution	-33.1			-33.1
Research and development	-40.1	+0.0		-40.1
General and administration	-5.8			-5.8
Operating profit	43.5	+0.6		44.1
Financing costs	-0.1			-0.1
Other financial income (expense)	0.3			0.3
Profit before taxes	43.8	+0.6		44.4
Income taxes	-11.8	-0.2		-12.0
Net income	32.0	+0.4		32.4
Chugai shareholders	31.5	+0.4		32.0
Non-controlling interests	0.5			0.5

(Billions of JPY)

(Non-Core items)

- Intangible assets:
Amortization of intangible assets +0.6
Impairment non
- Others
Environmental costs non

Core net income attributable to Chugai shareholders 32.0

(Millions of shares)

Weighted average number of shares and equity securities in issue used to calculate diluted earnings per share

547

(JPY)

Core EPS 58.45



Financial Overview Jan - Jun

(Billions of JPY)	2015 Jan - Jun vs. Revenues		2016 Jan - Jun vs. Revenues		Growth	
Revenues	240.2		247.5		+7.3	+3.0%
Sales	232.6		237.2		+4.6	+2.0%
excl. Tamiflu	225.9		230.0		+4.1	+1.8%
Domestic	179.1		184.2		+5.1	+2.8%
Export to Roche	37.2		37.4		+0.2	+0.5%
Other overseas	9.6		8.4		-1.2	-12.5%
Tamiflu	6.7		7.3		+0.6	+9.0%
Ordinary	6.7		7.3		+0.6	+9.0%
Govt. stockpiles, etc.	0.0		0.0		0.0	0.0%
Royalties and other operating income	7.5		10.3		+2.8	+37.3%
Cost of sales	-116.6	48.5%	-124.4	50.3%	-7.8	+6.7%
Gross profit	123.6	51.5%	123.1	49.7%	-0.5	-0.4%
Operating expenses	-77.7	32.3%	-79.0	31.9%	-1.3	+1.7%
Operating profit	45.9	19.1%	44.1	17.8%	-1.8	-3.9%
Financing costs	-0.0		-0.1		-0.1	-
Other financial income (expense)	0.7		0.3		-0.4	-57.1%
Income taxes	-14.0		-12.0		+2.0	-14.3%
Net income	32.5	13.5%	32.4	13.1%	-0.1	-0.3%
EPS (JPY)	58.30		58.45		+0.15	+0.3%

(Billions of JPY)

- Royalties and other operating income +2.8
Increase in Actemra-related revenue, etc.
- Other financial income (expense) -0.4
Exchange gains/losses +3.8
Gains/Losses on derivatives (Gains/Losses on foreign exchange forward contracts) -4.1

Cost of sales ratio vs. Sales

2015 Jan - Jun	2016 Jan - Jun
50.1%	52.4%

Average exchange rate (JPY)

	2015 Jan - Jun	2016 Jan - Jun
1 CHF	126.88	113.81
1 EUR	134.27	124.77
1 USD	120.24	111.79
1 SGD	89.10	80.96

Year on Year

Innovation all for the patients




A member of the Roche group


Sales (excl. Tamiflu) Jan - Jun

Sales by Disease Area, Year on Year Comparisons

(Billions of JPY)



Sales by Products, Year on Year Changes



(): FY2016 Actual

%: Year-on-year percentage change



Tamiflu Sales Performance


(Billions of JPY)		Fiscal Term Sales														Forecast	Seasonal Sales
		FY2010.12		FY2011.12		FY2012.12		FY2013.12		FY2014.12		FY2015.12		FY2016.12			
		Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec		
Ordinary	2009-10	1.4														26.6	
	2010-11		0.2	4.1												4.3	
	2011-12				1.3	7.8										9.1	
	2012-13						2.4	8.2								10.6	
	2013-14								1.9	7.0						9.0	
	2014-15										5.8	6.7				12.6	
	2015-16												1.5	7.3		8.7	
	2016-17														0.4	-	
Ordinary		1.6	(-34.6)	5.4	(+3.8)	10.2	(+4.8)	10.1	(-0.1)	12.9	(+2.8)	8.2	(-4.7)	7.6	(-0.6)		
Govt. Stockpiles etc.	2009-10	10.6														36.2	
	2010-11		5.9	0.5												6.4	
	2011-12				2.8	0.4										3.2	
	2012-13						1.5	0.8								2.3	
	2013-14								0.1	0.1						0.2	
	2014-15										0.1	0.0				0.1	
	2015-16												0.0	0.0		0.0	
	2016-17														1.0	-	
Govt. Stockpile etc.		16.6	(-23.4)	3.3	(-13.3)	1.9	(-1.4)	0.9	(-1.0)	0.2	(-0.7)	0.0	(-0.2)	1.0	(+1.0)		
Total		12.0	6.1	4.6	4.1	8.1	3.9	9.0	2.0	7.1	5.9	6.7	1.5	7.3	1.3		
		18.2	(-58.0)	8.7	(-9.5)	12.0	(+3.3)	11.0	(-1.0)	13.0	(+2.0)	8.2	(-4.8)	8.6	(+0.4)		



Year on Year (Core)

Operating Profit Jan - Jun

(Billion of JPY)



(Billions of JPY)	2015 Jan - Jun	2016 Jan - Jun	Growth
Revenues	240.2	247.5	+7.3
Cost of sales	-116.6	-124.4	-7.8
Gross profit	123.6	123.1	-0.5
of which Sales	116.1	112.8	-3.3
Royalties, etc.	7.5	10.3	+2.8
Marketing and distribution	-34.6	-33.1	+1.5
Research and development	-37.3	-40.1	-2.8
General and administration	-5.8	-5.8	0
Operating profit	45.9	44.1	-1.8

- Decrease in gross profit from sales -3.3
Cost of sales ratio to sales worsened due to HIP revision and supply price reduction on Actemra export, etc.
- Increase in royalties and other operating income +2.8
- Decrease in marketing and distribution +1.5
FX impact and decrease in various expenses
- Increase in research and development expenses -2.8
Progress of projects, etc.

Year on Year (Core)

Financial Overview Apr – Jun

Innovation all for the patients



Roche A member of the Roche group

(Billions of JPY)

(Billions of JPY)	2015 Apr – Jun vs. Revenues		2016 Apr – Jun vs. Revenues		Growth	
Revenues	123.1		127.6		+4.5	+3.7%
Sales	119.2		121.6		+2.4	+2.0%
excl. Tamiflu	119.2		121.4		+2.2	+1.8%
Domestic	95.2		96.4		+1.2	+1.3%
Export to Roche	19.2		20.9		+1.7	+8.9%
Other overseas	4.8		4.1		-0.7	-14.6%
Tamiflu	0.0		0.3		+0.3	-
Ordinary	0.0		0.3		+0.3	-
Govt. stockpiles, etc.	-		-		-	-
Royalties and other operating income	3.9		6.0		+2.1	+53.8%
Cost of sales	-59.1	48.0%	-63.5	49.8%	-4.4	+7.4%
Gross profit	63.9	51.9%	64.1	50.2%	+0.2	+0.3%
Operating expenses	-39.5	32.1%	-40.4	31.7%	-0.9	+2.3%
Operating profit	24.4	19.8%	23.7	18.6%	-0.7	-2.9%
Financing costs	-0.0		-0.0		0.0	0.0%
Other financial income (expense)	0.2		0.2		0.0	0.0%
Income taxes	-7.4		-6.4		+1.0	-13.5%
Net income	17.2	14.0%	17.5	13.7%	+0.3	+1.7%
EPS (JPY)	30.76		31.51		+0.75	+2.4%

• Decrease in gross profit from sales -2.0

Cost of sales ratio to sales worsened due to HIP revision and impact of supply price reduction on Actemra export, etc.

• Increase in royalties and other operating income +2.1

• Increase in operating expenses -0.9

Decrease in marketing and distribution FX impact and decrease in various expenses +1.4

Increase in research and development Progress of projects, etc. -2.1

Increase in general and administration -0.1

Cost of sales ratio vs. Sales

2015 Apr – Jun	2016 Apr – Jun
49.6%	52.2%

vs. Forecast (Core)

Innovation all for the patients



Roche A member of the Roche group

Financial Progress Jan – Jun

(Billions of JPY)	Actual	Forecast on Jan 28		2015 Progress*
	2016 Jan – Jun	2016 Jan – Dec	Progress	
Revenues	247.5	495.0	50.0%	48.2%
Sales	237.2	475.4	49.9%	49.7%
excl. Tamiflu	230.0	466.8	49.3%	49.1%
Domestic	184.2	379.0	48.6%	47.4%
Export to Roche	37.4	70.5	53.0%	59.0%
Other overseas	8.4	17.3	48.6%	50.3%
Tamiflu	7.3	8.6	84.9%	81.7%
Royalties and other operating income	10.3	19.6	52.6%	24.7%
Cost of sales	-124.4	-254.0	49.0%	48.8%
Gross profit	123.1	241.0	51.1%	47.5%
Operating expenses	-79.0	-170.0	46.5%	45.9%
Operating profit	44.1	71.0	62.1%	50.6%
EPS (JPY)	58.45	92.54	63.2%	50.1%

* Jan – Jun progress versus Jan – Dec.

vs. Forecast (Core)

Innovation all for the patients



Roche A member of the Roche group

Sales Progress (excl. Tamiflu) Jan – Jun

(Billions of JPY)	Actual	Forecast	Progress	2015
	2016 Jan – Jun	2016 Jan – Dec		Progress*
Sales excl. Tamiflu	230.0	466.8	49.3%	49.1%
Domestic	184.2	379.0	48.6%	47.4%
Oncology	107.0	220.3	48.6%	47.2%
Avastin	45.3	93.4	48.5%	47.2%
HER2 Franchise	26.4	53.9	49.0%	48.0%
Herceptin	16.6	34.9	47.6%	48.3%
Perjeta	5.7	11.3	50.4%	47.2%
Kadcyla	4.2	7.6	55.3%	46.6%
Xeloda	6.1	12.6	48.4%	47.7%
Tarceva	5.6	12.5	44.8%	47.4%
Alecensa	5.2	9.6	54.2%	38.8%
Bone and Joint	41.5	85.8	48.4%	47.2%
Actemra	14.3	29.7	48.1%	47.0%
Edirol	12.4	25.6	48.4%	45.9%
Bonviva	3.6	7.7	46.8%	44.4%
Renal	19.9	40.8	48.8%	47.1%
Mircera	11.4	23.7	48.1%	46.2%
Oxarol	4.7	9.2	51.1%	46.5%
Epogin	2.5	5.3	47.2%	49.2%
Transp., Immun., Infectious	6.7	14.1	47.5%	44.7%
CellCept	3.7	8.1	45.7%	47.1%
Copegus	1.0	1.5	66.7%	20.7%
Pegasys	0.3	0.9	33.3%	68.4%
Others	9.1	18.0	50.6%	52.5%
Overseas	45.8	87.8	52.2%	56.9%
Export to Roche	37.4	70.5	53.0%	59.0%
Actemra	36.0	68.0	52.9%	59.4%
Alecensa	1.4	2.5	56.0%	-
Other overseas	8.4	17.3	48.6%	50.3%

* Jan – Jun progress versus Jan – Dec.

vs. Forecast (Core)

Innovation all for the patients



Roche A member of the Roche group



Impact from Foreign Exchange

(Billions of JPY)	FX impact Jan – Jun 2016 (FX impact vs. Forecast)	
Revenues	-1.3	
	Sales	-0.7
	Royalties and other operating income	-0.6
Cost of sales	Cost of sales	+0.8
Operating expenses	Expenses	+0.9
Operating profit	+0.4	

Actual / Forecast rate* (JPY)	2015 Jan - Jun Actual	2016 Jan -Dec Forecast	2016 Jan - Jun Actual
1CHF	126.88	127.00	113.81
1EUR	134.27	134.00	124.77
1USD	120.24	120.00	111.79
1SGD	89.10	87.00	80.96

[Reference]
Historical exchange rate to the JPY

Forecast rate



* Actual: average exchange rate for the period of Jan - Jun

vs. 2015 Year End

Balance Sheet Items

< Assets, Liabilities, and Net Assets >

(Billions of JPY)	2015 Dec	2016 Jun	Change
Trade accounts receivable	134.5	124.5	- 10.0
Inventories	161.1	173.5	+ 12.4
Trade accounts payable	-41.2	-37.5	+ 3.7
Other net working capital	-39.8	-16.5	+ 23.3
Net working capital	214.6	244.1	+ 29.5
Property, plant and equipment	153.5	157.6	+ 4.1
Intangible assets	13.5	16.6	+ 3.1
Other long-term assets - net	-1.3	-2.4	- 1.1
Long-term net operating assets	165.8	171.8	+ 6.0
Net operating assets	380.4	415.9	+ 35.5
Debt	-0.7	-0.7	0.0
Marketable securities	134.4	109.4	- 25.0
Cash and cash equivalents	101.7	100.1	- 1.6
Net cash	235.4	208.8	- 26.6
Other non-operating assets - net	11.5	4.7	- 6.8
Net non-operating assets	246.8	213.5	- 33.3
Total net assets	627.3	629.4	+ 2.1
Total assets	787.4	766.9	- 20.5
Total liabilities	-160.1	-137.5	+ 22.6

Other net working capital: accrued receivable, accrued payable, accrued expenses, etc

Other long-term assets - net: long term prepaid expenses, long-term provisions, etc

Other non-operating assets - net: deferred income tax assets, accrued corporate tax, etc

FY2016 2Q Consolidated Financial Overview

Innovation all for the patients



Roche A member of the Roche group

● Increase in net working capital	+29.5
Decrease in trade accounts receivable	-10.0
Seasonal change, etc.	
Increase in inventories	+12.4
Decrease in trade accounts payable	+3.7
Increase in other net working capital	+23.3
Decrease in accounts payable for property, plant and equipment relating to plant for bio antibody API production	
● Increase in long-term net operating assets	+6.0
Increase in Property, plant and equipment	+4.1
Purchase of land for business in Totsuka and investment expenditure in production facilities, etc.	
● Decrease in net cash	-26.6
● Decrease in other non-operating assets - net	-6.8
● Equity ratio attributable to Chugai shareholders	+2.5% pts.
2016 Jun	82.0%
2015 Dec	79.5%

FX rate to the JPY (end of period)

	2015 Dec	2016 Jun
1 CHF	121.89	104.96
1 EUR	131.75	114.39
1 USD	120.52	102.83
1 SGD	85.20	76.27

vs. 2015 Year End


Net Cash

FY2016 2Q Consolidated Financial Overview

Innovation all for the patients



Roche A member of the Roche group



● Operating cash flow after adjustments	+53.3
Operating profit	+43.5
Depreciation and amortization, etc.	+9.8
● Total increase in net working capital, etc.	-18.5
Decrease in trade accounts receivable	+9.7
Increase in inventories	-13.8
Decrease in trade accounts payable	-3.5
Change in other net working capital, etc.	-11.0
● Total investment	-27.8
Investment in Property, plant and equipment	-24.2
Investment in plant for bio antibody APA production and purchase of land for business in Totsuka, etc.	-3.5
Investment in intangible assets	-3.5
Operating free cash flow	+7.0
● Others	-11.1
Treasury activities (interest income/expenses, foreign exchange gains/losses, etc.)	+1.7
Tax paid	-12.8
Free cash flow *3	-4.2

*1 Net effect of currency transactions on net cash, etc. = Transaction in own equity instruments + Net effect of currency translation on net cash(*2)

*2 It result from using different exchange rate types when consolidating overseas subsidiaries in financial statements, i.e. net cash using end of period exchange rate and free cash flow using average exchange rate. (Chugai defines this term based on International Accounting Standard (IAS) 7 and IAS 21)

*3 Our free cash flow (FCF) was calculated by taking operating free cash flow and subtracting dividends paid out. Due to the change in the definition used by Roche, our FCF from 2Q FY2016 is the cash flow before paid dividends are subtracted from operating cash flow. This is identical with the standard definition.

Year on Year

Free Cash Flow Jan - Jun

Innovation all for the patients



Roche A member of the Roche group

(Billions of JPY)	2015 Jan-Jun	2016 Jan-Jun	Change
Operating profit - IFRS basis	43.2	43.5	+0.3
Depreciation and impairment of Property, plant and equipment	7.0	7.5	+0.5
Amortization and impairment of intangible assets	2.6	0.7	-1.9
Other cash adjustment on operating profit	-0.7	1.5	+2.2
Operating profit, net of operating cash adjustments	52.1	53.3	+1.2
Increase (-) / decrease in trade accounts receivable	13.0	9.7	-3.3
Increase (-) / decrease in inventories	-6.7	-13.8	-7.1
Increase / decrease (-) in trade accounts payable	8.0	-3.5	-11.5
Change in other net working capital, etc.	-7.3	-11.0	-3.7
Total increase (-) / decrease in net working capital, etc.	7.0	-18.5	-25.5
Investment in Property, plant and equipment	-10.9	-24.2	-13.3
Investment in intangible assets	-2.9	-3.5	-0.6
Total investment	-13.8	-27.8	-14.0
Operating free cash flow	45.3	7.0	-38.3
as % of revenues	18.9%	2.8%	-16.1%pts.
Treasury activities (interest income/expenses, foreign exchange gains/losses, etc.)	2.6	1.7	-0.9
Tax paid	-16.0	-12.8	+3.2
Free cash flow *3	31.9	-4.2	-36.1
Dividends paid	-14.8	-17.9	-3.1
Transaction in own equity instruments *2	0.8	0.4	-0.4
Net effect of currency translation on net cash, etc. } *1	-1.4	-4.9	-3.5
Net change in net cash	16.5	-26.6	-43.1

● Total increase (-) / decrease in net working capital, etc.	-25.5
Increase (-) / decrease in trade accounts receivable	-3.3
Increase (-) / decrease in inventories	-7.1
Increase / decrease (-) in trade accounts payable	-11.5
Purchase timing	
Change in other net working capital, etc.	-3.7
● Total investment	-14.0
Investment in Property, plant and equipment	-13.3
Investment in plant for bio antibody production and purchase of land for business in Totsuka, etc.	
● Operating free cash flow	-38.3
● Operating free cash flow as % of revenues	-16.1%pts.
Revenues	+7.3

Average exchange rate (JPY)

	2015 Jan - Jun	2016 Jan - Jun
1CHF	126.88	113.81
1EUR	134.27	124.77
1USD	120.24	111.79
1SGD	89.10	80.96

*1 Net effect of currency transactions on net cash, etc. = Transaction in own equity instruments + Net effect of currency translation on net cash

*2 It result from using different exchange rate types when consolidating overseas subsidiaries in financial statements, i.e. net cash using end of period exchange rate and free cash flow using average exchange rate. (Chugai defines this term based on International Accounting Standard (IAS) 7 and IAS 21)

*3 Our free cash flow (FCF) was calculated by taking operating free cash flow and subtracting dividends paid out. Due to the change in the definition used by Roche, our FCF from 2Q FY2016 is the cash flow before paid dividends are subtracted from operating cash flow. This is identical with the standard definition.

Overview of Development Pipeline

CHUGAI PHARMACEUTICAL CO., LTD.
Associate Vice President
Deputy General Manager of Research Division
Minoru Watanabe

July 21/22, 2016



Oncology Field

Projects under Development (as of 21 July, 2016)

	Phase I	Phase II	Phase III	Filed
Oncology	CKI27 / RG7304 (Japan / overseas) - solid tumors RG7596 / polatuzumab vedotin - NHL RG7604 / taselisib - solid tumors RG7440 / ipatasertib - solid tumors	GC33 (RG7686) / codrituzumab - HCC RG435 / Avastin - MPM ★	AF802 (RG7853) / Alecensa (overseas) - NSCLC [1L] RG1273 / Perjeta - breast cancer (adjuvant) - gastric cancer RG3502 / Kadcyla -breast cancer (adjuvant) GA101 (RG7159) / obinutuzumab - aggressive NHL - indolent NHL RG7446 / atezolizumab - NSCLC - NSCLC (adjuvant) - SCLC ★ - bladder cancer - MIBC (adjuvant) - renal cell carcinoma - breast cancer ★ RG435 / Avastin - renal cell carcinoma	AF802 (RG7853) / Alecensa (EU) - NSCLC [post-crizotinib]

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

NHL: non-Hodgkin's lymphoma

HCC: hepatocellular carcinoma

MPM: malignant pleural mesothelioma

NSCLC: non-small cell lung cancer

SCLC: small cell lung cancer

MIBC: muscle invasive bladder cancer

Letters in orange: in-house projects

★: Projects with advances in stages since 22 April, 2016



Primary Field Projects under Development (as of 21 July, 2016)

	Phase I	Phase II	Phase III	Filed
Bone & Joint			ED-71 / Ediolol (China) - osteoporosis	
Renal	EOS789 - hyperphosphatemia			
Autoimmune			MRA / Actemra - large-vessel vasculitis - giant cell arteritis (overseas) - systemic sclerosis SA237 - neuromyelitis optica★	
CNS	RG1662 / basmisanil - improvement of intellectual ability in individuals with Down syndrome		RG1450 / gantenerumab - Alzheimer's disease	
Others	PCO371 (overseas) - hypoparathyroidism	RG3637 / lebrikizumab - IPF CIM331 / nemolizumab - atopic dermatitis★ - pruritus in dialysis patients URC102 (South Korea) - gout	RG3637 / lebrikizumab - asthma ACE910 (RG6013) /emicizumab - hemophilia A	

In principle, completion of first dose is regarded as the start of clinical studies in each phase.
IPF: idiopathic pulmonary fibrosis

Letters in orange: in-house projects

★: Projects with advances in stages since 22 April, 2016

★: Multinational study managed by Chugai



Development Status

In-
licensed

RG435 / Avastin®

Cervical cancer (additional indication)

Approved in May 2016

Malignant pleural mesothelioma

Started P2 in July 2016

In-
licensed

RG7446 / atezolizumab

Small cell lung cancer

Started global P3 in June 2016

Breast cancer (triple negative)

Started global P3 in May 2016



Other Progress (1/2)

In-house

Marduox® Ointment

Psoriasis vulgaris (combination topical ointment)
Launched in June 2016

In-licensed

CellCept®

Lupus Nephritis (additional indication)
Approved in May 2016 (public knowledge-based application)

In-house

ERY974

Solid tumor
Decided to start development

In-house

GC33 / codrituzumab

RG7446 / atezolizumab

Hepatocellular carcinoma
Decided to start development in combination

In-licensed



Other Progress (2/2)

In-house

CIM331 / nemolizumab

- Entered license agreement with Galderma S.A. in July 2016

In-house

SA237 / RG6168

- Entered license agreement with Roche in June 2016
- Designated as an orphan drug for the expected indication of neuromyelitis optica in June 2016 (EU)

Collaboration

Concluded a comprehensive collaboration agreement for advanced research in immunology with Osaka University Immunology Frontier Research Center (IFReC) in May 2016



Oncology Field

Data Presentation / Results of Clinical Trials

In-house

AF802 / Alecensa®

Detailed data of J-ALEX study (P3 in Japan) was presented at the American Society of Clinical Oncology in June 2016

In-licensed

GA101 / obinutuzumab

- Showed prolonged progression-free survival compared to Rituxan® in global P3 (GALLIUM study) for previously untreated follicular lymphoma in May 2016
- Global P3 (GOYA study) for previously untreated diffuse large B-cell lymphoma did not meet its primary endpoint in July 2016



Primary Field

Data Presentation / Results of Clinical Trials

In-house

MRA / Actemra®

- Efficacy of subcutaneous injection confirmed in Dose Interval Reduction study for rheumatoid arthritis patients who inadequately respond to bi-weekly dose in May 2016
- Overseas P3 study for Giant Cell Arteritis (GiACTA study) achieved primary and secondary endpoint in June 2016

In-house

ACE910 / emicizumab

- Phase I data in patients with hemophilia A published in The New England Journal of Medicine in May 2016
- Updated long-term P1/2 study results to be presented at the World Federation of Hemophilia in July 2016



ERY974 (TRAB): Mode of Action

What is T-cell redirecting antibody (TRAB)?

- TRAB is a bispecific antibody intended to create a short bridge between CD3 on T cells and tumor antigen on tumor cells
- TRAB activates T cells in a tumor antigen-dependent manner and demonstrates strong cytotoxicity against tumor cells


What is ERY974?

- Chugai's first TRAB
- Targeting glypican-3 (GPC3) expressed in tumor cells
- Expected to induce strong antitumor effects on various GPC3 positive tumors

What is GPC3?

- GPC3 is a heparan sulfate proteoglycan expressed in multiple types of tumor cells, such as hepatocellular carcinoma^{1,2)}, gastric cancer, esophageal cancer^{3,4)} and so on.


1) Filmus. Glycobiology. 2001;11:19R-23R5.
2) Yorita et al., Liver Int. 2011;31:120-131.
3) Ushiku et al., Cancer Sci. 2009;100:626-636.
4) Mounajjed et al., Human Pathology. 2013;44:542-550.





Combination of GC33/codrituzumab (Anti-GPC3 Mab) and Atezolizumab (Anti-PDL1 Mab)

- Codrituzumab is an IgG1 type humanized monoclonal antibody against GPC3
- In the global single agent P2 study for advanced HCC conducted with Roche, codrituzumab was well tolerated but did not show clinical benefit
- As the results of retrospective analysis, high GPC3 expression in tumors or enough immune status was associated with prolonged overall survival¹⁾
- In combination with atezolizumab, induction of acquired immunity in addition to innate immunity contribution would augment antitumor activity



(Chen DS and Mellman I, Immunity, 2013; 39: 1-10)

1) Abou-Alfa G et al., J Hepatol. 2016, in press.

Framework of IFReC-Chugai Comprehensive Collaboration


Overview of Development Pipeline

Innovation all for the patients



Roche A member of the Roche group

~ New academia-industry alliance collaborating from the stage of autonomous basic research at IFReC ~






Projected Submissions (Post PoC NMEs and Products)

Filed

ALECENSA
(AF802/RG7853)
NSCLC
[post-crizotinib]
(EU)

in-house NME line extension
in-licensed ■
 ■





Updates on the Development Requests for Unapproved Drugs/Indications

Review Committee of Development Requests for Unapproved Drugs/Indication

- Ten indications (including additional dosages and administrations) of eight products from the 1st round requests have been approved
- Three indications of three products from the 2nd round requests have been approved

	Product	Indication	Current Situation
2nd round requests	CellCept®	Lupus nephritis	Approved (May 13, 2016)

- Among candidates at the 3rd round, two indications of two products were requested for development

	Product	Indication	Current Situation
3rd round requests	Tamiflu®	Addition of dosage and administration for newborn and infant	Submitted company opinion and waiting for evaluation by the committee
	Xeloda®	Adjuvant chemotherapy for rectal cancer	Filed (Public Knowledge–based application on March 2, 2016)

Letters in red: projects with change in status since January 28, 2016

Contacts: Corporate Communications Dept.

Media Relations Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607

e-mail: pr@chugai-pharm.co.jp

Koki Harada, Hiroshi Araki, Sachiyo Yoshimura, Mitsuka Saito

Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607

e-mail: ir@chugai-pharm.co.jp

Toshiya Sasai, Takayuki Sakurai, Tomoko Shimizu,
Tomoyuki Shimamura